Indication
Lennox-Gastaut epilepsy
Lennox-Gastaut epilepsy, commonly referred to as Lennox-Gastaut syndrome (LGS), is a severe, lifelong developmental and epileptic encephalopathy that typically manifests in early childhood between the ages of two and eight years. Read more about Lennox-Gastaut epilepsy
201 drugs 101 manufacturers
Drugs that treat it
Common Lennox-Gastaut epilepsy therapies.
LAMICTAL (lamotrigine)
LAMICTAL (lamotrigine)
FELBATOL (felbamate)
CLONAZEPAM
TOPAMAX (topiramate)
TOPIRAMATE
LAMICTAL (ORANGE) (lamotrigine)
BANZEL (rufinamide)
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonLennox-Gastaut epilepsy, commonly referred to as Lennox-Gastaut syndrome (LGS), is a severe, lifelong developmental and epileptic encephalopathy that typically manifests in early childhood between the ages of two and eight years.
Primarily affecting the central nervous system, it is clinically characterized by a triad of multiple drug-resistant seizure types—most notably tonic, atonic, and atypical absence seizures—alongside moderate to severe cognitive impairment and behavioral disturbances.
The defining pathophysiologic neurodiagnostic features include generalized interictal slow spike-and-wave discharges of less than 3 Hz during wakefulness and generalized paroxysmal fast activity during sleep.
Frequent tonic and atonic episodes frequently trigger precipitous drop attacks, presenting a high risk for recurrent injury and status epilepticus.
- nih.gov
Lennox-Gastaut epilepsy, commonly referred to as Lennox-Gastaut syndrome (LGS), is a severe, lifelong developmental and epileptic encephalopathy that typically manifests in early childhood between the ages of two and eight years
- nih.gov
Lennox-Gastaut epilepsy, commonly referred to as Lennox-Gastaut syndrome (LGS), is a severe, lifelong developmental and epileptic encephalopathy that typically manifests in early childhood between the ages of two and eight years Primarily affecting the central nervous system, it is clinically characterized by a triad of multiple drug-resistant seizure types—most notably tonic, atonic, and atypical absence seizures—alongside moderate to severe cognitive impairment and behavioral disturbances
- ucb.com
Lennox-Gastaut epilepsy, commonly referred to as Lennox-Gastaut syndrome (LGS), is a severe, lifelong developmental and epileptic encephalopathy that typically manifests in early childhood between the ages of two and eight years
- medlineplus.gov
Primarily affecting the central nervous system, it is clinically characterized by a triad of multiple drug-resistant seizure types—most notably tonic, atonic, and atypical absence seizures—alongside moderate to severe cognitive impairment and behavioral disturbances The defining pathophysiologic neurodiagnostic features include generalized interictal slow spike-and-wave discharges of less than 3 Hz during wakefulness and generalized paroxysmal fast activity during sleep Frequent tonic and atonic...
- nih.gov
Primarily affecting the central nervous system, it is clinically characterized by a triad of multiple drug-resistant seizure types—most notably tonic, atonic, and atypical absence seizures—alongside moderate to severe cognitive impairment and behavioral disturbances
- nih.gov
The defining pathophysiologic neurodiagnostic features include generalized interictal slow spike-and-wave discharges of less than 3 Hz during wakefulness and generalized paroxysmal fast activity during sleep Frequent tonic and atonic episodes frequently trigger precipitous drop attacks, presenting a high risk for recurrent injury and status epilepticus
- epilepsydiagnosis.org
The defining pathophysiologic neurodiagnostic features include generalized interictal slow spike-and-wave discharges of less than 3 Hz during wakefulness and generalized paroxysmal fast activity during sleep
- aan.com
Frequent tonic and atonic episodes frequently trigger precipitous drop attacks, presenting a high risk for recurrent injury and status epilepticus
Personalize your experience
Follow Lennox-Gastaut epilepsy and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.